FDA Disapproves "Pink Viagra"

Cristen Conger

Following up on an earlier post about flibanserin, nicknamed "pink viagra" by the media, the Food & Drug Administration's advisory panel voted against approving the drug. Specifically, the panel decided that the pill developed by global pharmaceutical firm Boehringer-Ingelheim didn't outperform the placebo significantly enough to earn it a spot in the healthcare marketplace. Women in the clinical trial who were taking flibanserin experienced a slight uptick in "sexually satisfying experiences" from 2.8 to 4.5 times per month, compared to 3.7 satisfying events for women on the placebo.

Remember that unlike Viagra, women would have to take flibanserin every day over a period of time. That mean's downing about 30 pills a month in exchange for 0.8 more sexually satisfying events -- not even a whole "event"! In related reproductive news, the U.S. advisory panel did approve ellaOne, a new 5-day emergency contraception that's already in use in Europe.

Follow Cristen & Molly from Stuff Mom Never Told You on Twitter and Facebook.